Division of Gynecologic Oncology, Regina Elena National Cancer Institute, Rome, Italy.
Eur J Surg Oncol. 2011 Apr;37(4):364-9. doi: 10.1016/j.ejso.2010.12.001. Epub 2010 Dec 30.
To evaluate the feasibility and morbidity of total laparoscopic class C2 radical hysterectomy (TLRH) with pelvic lymphadenectomy in patients with locally advanced cervical cancer stage IB2 to IIB after neoadjuvant chemotherapy (NACT).
A prospective study was conducted from October 2004 to September 2009. Cervical cancer patients, stage IB2-IIB with complete clinical response after 3 courses of NACT with paclitaxel 175 mg/m(2), ifosfamide 5 g/m(2) and cisplatin 75 mg/m(2) (TIP) underwent TLRH.
Forty patients were included, with a median age of 46 years (range, 25-65), BMI of 24 kg/m(2) (range, 15-49). FIGO staging was IB2 in 23, IIA > 4 cm in 6 and IIB in 11 patients. Four patients required conversion to laparotomy. Pathological evaluation showed 9 complete response (pCR), 9 partial response (pPR1) with microscopic tumour, and 15 partial response (pPR2) with macroscopic tumour. Three patients had no response. The median operative time was 305 min (range, 215-430); the median estimated blood loss was 250 ml (range, 100-400), with four postoperative blood transfusion; the median number of removed pelvic lymph nodes was 25 (range, 11-64). The median length of hospital stay was 6 days (range, 3-12). The median follow-up time was 37 months (range, 10-69), with three patients having a recurrence. One patient died of disease (DOD) after 12 months.
TLRH can be safely performed in patients with stage IB2-IIB carcinoma of cervix after NACT, with advantages of minimal blood loss and morbidity.
评估新辅助化疗(NACT)后局部晚期宫颈癌 IB2 至 IIB 期患者行全腹腔镜 C2 级根治性子宫切除术(TLRH)加盆腔淋巴结清扫术的可行性和发病率。
一项前瞻性研究于 2004 年 10 月至 2009 年 9 月进行。接受紫杉醇 175mg/m²、异环磷酰胺 5g/m²和顺铂 75mg/m²(TIP)3 个疗程后完全临床缓解的宫颈癌患者,临床分期 IB2-IIB 期,行 TLRH。
共纳入 40 例患者,中位年龄 46 岁(25-65 岁),体重指数 24kg/m²(15-49kg/m²)。FIGO 分期 IB2 者 23 例,>4cm 的 IIA 期 6 例,IIB 期 11 例。4 例患者需要中转开腹。病理评估示完全缓解(pCR)9 例,镜下肿瘤残留的部分缓解(pPR1)9 例,肉眼肿瘤残留的部分缓解(pPR2)15 例。3 例患者无反应。中位手术时间 305min(215-430min);中位估计出血量 250ml(100-400ml),4 例术后输血;中位切除盆腔淋巴结数 25 个(11-64 个)。中位住院时间 6 天(3-12 天)。中位随访时间 37 个月(10-69 个月),3 例患者复发。1 例患者在 12 个月时死于疾病(DOD)。
NACT 后行 TLHR 治疗 IB2-IIB 期宫颈癌安全可行,具有出血量少、发病率低的优点。